



OPEN

Chitosan overlaid Fe₃O₄/rGO nanocomposite for targeted drug delivery, imaging, and biomedical applications

Viswanathan Karthika^{1,2}, Mohamad S. AlSalhi^{2,3}✉, Sandhanasamy Devanesan^{2,3}, Kasi Gopinath¹, Ayyakannu Arumugam⁴ & Marimuthu Govindarajan^{5,6}

A hybrid and straightforward nanosystem that can be used simultaneously for cancer-targeted fluorescence imaging and targeted drug delivery *in vitro* was reported in this study. A chitosan (CS) polymer coated with reduced graphene oxide (rGO) and implanted with Fe₃O₄ nanoparticles was fabricated. The fundamental physicochemical properties were confirmed via FT-IR, XRD, FE-SEM, HR-TEM, XPS, and VSM analysis. The *in vivo* toxicity study in zebrafish showed that the nanocomposite was not toxic. The *in vitro* drug loading amount was 0.448 mg/mL⁻¹ for doxorubicin, an anticancer therapeutic, in the rGO/Fe₃O₄/CS nanocomposite. Furthermore, the pH-regulated release was observed using folic acid. Cellular uptake and multimodal imaging revealed the benefit of the folic acid-conjugated nanocomposite as a drug carrier, which remarkably improves the doxorubicin accumulation inside the cancer cells over-express folate receptors. The rGO/Fe₃O₄/CS nanocomposite showed enhanced antibiofilm and antioxidant properties compared to other materials. This study's outcomes support the use of the nanocomposite in targeted chemotherapy and the potential applications in the polymer, cosmetic, biomedical, and food industries.

One current focus of the scientific community is combating cancer using nanotherapeutics, chemotherapy, and gene therapy. Current strategies for the drug delivery of cancer therapeutics are focused on increasing the drug concentration at the target site and reducing the systemic distribution. In this regard, functionalized nanoparticles (NPs) are of interest because they can prevent the systemic metabolism and subsequent elimination of the drug, thus ensuring pharmacological effect with less toxicity¹. Advancements in nanoscience have facilitated the selective transportation of drugs into the target site by a unique mechanism (ligand-mediated targeting and receptor-mediated targeting molecules)—this makes to deliver the specific antitumor molecule to the cancer tissue. The sensitive nanocarriers are size- and dimension-dependent. After exposure to an external stimulus, such as pH, enzymatic systems, magnetic gradient, temperature, and ultrasound, the nanocarriers change their physicochemical properties^{1,2}. Superparamagnetic Fe₃O₄ NPs have gained attention for their multifunctionality, including target-based carriage, localized hyperthermia therapy, stem cell labeling and tracking, and contrast agents for magnetic resonance imaging (MRI)^{3–6}.

Additionally, nanocomposites with these superparamagnetic NPs and a 2-dimensional graphene derivative with a large surface area can be used to rational design the drug delivery system. Thus, nanocomposites with a high drug loading capacity and magnetically controlled carrier can be accomplished simultaneously. The preferred graphene derivative for drug loading and delivery efficiency is graphene oxide (GO), because its viable surface chemistry contains layers of graphene sheets with various organic functional groups, such as carboxylic acid, epoxide, and hydroxide, on its surface⁷. The peripheral carboxylic group (–COO) can stabilize the colloidal system and create a pH-responsive negative charge surface. However, the basal plane having hydroxyl (–OH)

¹Department of Packaging, Yonsei University, 1 Yonseidaegil, Wonju-si, Gangwon-do 26493, South Korea. ²Research Chair in Laser Diagnosis of Cancers, College of Science, Department of Physics and Astronomy, King Saud University, Riyadh 11451, Kingdom of Saudi Arabia. ³Department of Physics and Astronomy, College of Science, King Saud University, Riyadh 11451, Kingdom of Saudi Arabia. ⁴Department of Botany, Alagappa University, Karaikudi, Tamil Nadu 630 003, India. ⁵Department of Zoology, Unit of Vector Control, Phytochemistry and Nanotechnology, Annamalai University, Annamalainagar, Tamil Nadu 608 002, India. ⁶Department of Zoology, Unit of Natural Products and Nanotechnology, Government College for Women (Autonomous), Kumbakonam, Tamil Nadu 612 001, India. ✉email: malsalhy@gmail.com

and the epoxide ($-O^-$) groups results in the weak chemical interaction, such as H-bonding, or chemical interaction causing the transpire on the surface^{8–11}. Even the entire areas of GO can be used for drug loading and non-covalent functionalization because of the possible π - π interactions on the basal plane. Thus, when designing an efficient drug delivery system, GO acts as a surfactant to stabilize hydrophobic molecules due to its amphiphilic nature^{12,13}. However, Wang et al.¹⁴ reported that pure GO is toxic to cells in vitro and animals, as the kidneys cannot empty it, thereby resulting in the granuloma formation in the lung or cell apoptosis lung granuloma formation even though apparent toxicity did not observe in the lower dose and moderate dose approximately 0.1 mg and 0.25 mg, respectively. Thus, GO must be coated with polymers, such as chitosan (CS), and polyethylene glycol, to improve its solubility. CS is made of two types of structural units: 2-amino-2-deoxy-d-glucose and N-acetyl-2-amino-2-deoxy-d-glucose linked by a $\beta(1 \rightarrow 4)$ bond, and CS is derived from chitin¹⁵. CS is a polycationic biopolymer, abundant in different crustacean shells like crab, shrimp and crawfish. CS is a low-cost material with biodegradable and biocompatible properties, and ease of chemical modification. CS possesses chelation property and selectively binds with metal ions and biomolecules like proteins, cholesterol and tumor cells. Due to this property, CS is widely used in the food industry, pharmaceutical, and water management farms. CS possesses properties useful in the medical field to inhibit tumor cells, as antimicrobial agents, as a wound-healing agent and as immunostimulant¹⁶. CS-coated GO has improved solubility and drug loading capability, in addition to its increased potential to distribute the drug molecule at the tumor site, which has an acidic environment^{7,9,15}.

When evaluating the designed drug delivery system's efficacy, the loaded drugs and ligands should be considered. Doxorubicin (DOX) is one of the best therapeutic agents for cancers. The cytotoxicity and DNA cleavage can be occurred through binding to DNA (intercalation mode) or reacting with topoisomerase II^{16,17}. Folic acid (FA) is a highly selective ligand that binds to the folate receptor¹⁸. This ligand also has high target specificity to various types of cancer cells. Binding of the carrier molecules with FA improves the efficiency and reduces the adverse effects of the drug molecules^{19,20}. The pH-responsive release behavior and anticancer activity of Dox-loaded, FA-conjugated, GO-Fe₃O₄ nanocomposites were reported in the previous studies. However, The combination of rGO/Fe₃O₄/CS was a novel attempt. Such a facile protocol was resulted in Fe₃O₄ with a size of less than 35 nm. This combination can be applied to the drug delivery system because it presented an appropriate cancer therapy result. Briefly, rGO can interact with DOX through a π - π bond and hence enhance the drug loading capacity, in which Fe₃O₄, as a magnetic agent, can readily move through the therapy without any external magnetic field. Besides, the biopolymeric backbone of nanocomposite (CS) can control the neutral pH's release behavior.

Furthermore, FA is a receptor and DOX is a model drug. Therefore, the current attempt was carried out as a novel study, in which there has been no report on rGO/Fe₃O₄/CS/FA/DOX combination. Accordingly, this study aimed to achieve efficient drug loading, release, and fluorescence imaging with chemo-photothermal combination therapy for cancer; herein, we report a biocompatible theragnostic nano platform, rGO/Fe₃O₄/CS, which was synthesized via a solvothermal method and studied as a targeted drug delivery system with DOX and FA (DOX/rGO/Fe₃O₄/CS/FA).

Results and discussion

Chemical bond analysis using FT-IR. The chemical properties and bonding nature of the synthesized rGO/Fe₃O₄ (5%) and rGO/Fe₃O₄/CS (15%) nanocomposites were studied by infrared spectroscopy, and the obtained spectra are shown in Fig. 1. The nanocomposites' spectra were primarily compared with the FT-IR spectra of pure GO, CS, and Fe₃O₄ NPs (Fig. 1) to ensure the presence of the respective materials in both nanocomposites. The peaks present at 3563 cm⁻¹, 2036 cm⁻¹, 1410 cm⁻¹, and 959 cm⁻¹ in the spectra of the pure GO corresponds to the O-H, C=O, C-OH, and C-O functional groups, respectively, (Fig. 1). In pure CS, peaks at 968 cm⁻¹, 2006 cm⁻¹, and 2975 cm⁻¹ corresponded to the characteristic stretching vibrations of C-O, NH₂, and C-H bonds, respectively (Fig. 1)²¹. A common broad peak at 3378 cm⁻¹ present in the FT-IR spectra of both GO and CS was credited to the hydroxyl groups present in the adsorbed water molecules present at the surface of both GO and CS. In the Fe₃O₄ NP, the peak at 604 cm⁻¹ represented the presence of a Fe-O bond in the material (Fig. 1)^{20,22}. Furthermore, the peak at 604 cm⁻¹ attributed to the stretching vibration of the Fe-O bond. This band was shifted to 952 cm⁻¹, due to the bonding of Fe₃O₄ NPs with the $-COO^-$ groups on the rGO surface²³. The FT-IR spectra of the nanocomposites showed a synergistic effect between the pure GO and the Fe₃O₄ NPs on the properties of CS. In the IR spectrum of GO, Fe₃O₄ NPs, CS, the peaks at 3933, 3322, 2975, 2840, 2662, 2036, 1634, 1440, 968 and 604 cm⁻¹ shifted to 3940, 3329, 2984, 2835, 2655, 2045, 1545, 1473, and 952 cm⁻¹, respectively, which might exhibit the successful formation of rGO/Fe₃O₄/CS nanocomposites. The positive shift of the -OH peak in the rGO/Fe₃O₄/CS composite indicated an H-bond interaction between fillers and the CS (Fe₃O₄ and GO)²⁴.

Crystal structural analysis using XRD. As shown in Fig. 2, the crystallographic properties of both rGO/Fe₃O₄ and rGO/Fe₃O₄/CS nanocomposites were obtained using X-ray powder diffraction (XRD) patterns. A sharp peak at $2\theta = 12.7^\circ$ and a broad peak at $2\theta = 25.9^\circ$ corresponding to the (001) and (002) planes, respectively, confirmed the formation of GO with an interlayer thickness of about 8.75 Å and weak amorphous peak at $2\theta = 19.2^\circ$ could be attributed to CS as shown in Fig. 2²⁵. The peaks present at the 2θ values, 30.07°, 35.4°, 37.05°, 43.05°, 53.41°, 56.93°, and 62.52°. Both the XRD patterns appeared due to the diffraction of X-ray by the (220), (311), (222), (400), (422), (333), and (440) planes, respectively. It is apparent evidence for the existence of the Fe₃O₄ phase in both nanocomposites. The Scherrer equation was used to calculate the average crystalline size of the Fe₃O₄ NPs in the rGO/Fe₃O₄ (20, 37) and rGO/Fe₃O₄/CS (60 nm)²⁶. The obtained Fe₃O₄ phase correlated well with the standard JCPDS card No: 82-1533 with a face-centered cubic crystal structure. The diffraction pattern of both composites' intensity was low and peaks shifted corresponding to GO/rGO or CS. It may be due to the




Figure 1. Fourier transformed-infrared (FT-IR) spectra of graphene oxide (GO), chitosan (CS), Fe_3O_4 , rGO/ Fe_3O_4 (5%), and rGO/ Fe_3O_4 /CS (15%) nanocomposites.




Figure 2. X-ray diffraction (XRD) pattern of graphene oxide (GO), chitosan (CS), Fe_3O_4 , rGO/ Fe_3O_4 (3%), rGO/ Fe_3O_4 (5%), rGO/ Fe_3O_4 /CS (5%), and rGO/ Fe_3O_4 /CS (15%) nanocomposites.

crystalline nature of rGO or CS, which has sharp diffraction peaks that suppress the low intensity of Fe_3O_4 NPs peaks.

FE-SEM analysis. The GO morphology was observed using field emission -scanning electron microscopy (FE-SEM), by which GO illustrated a network structure with a high specific surface area and minimum thickness formed by the GO nanosheets (Fig. 3). In pure CS (Fig. 3), smaller particles were agglomerated and formed large clusters with irregular shapes. The pure Fe_3O_4 NPs had a spherical shape with a particle size distribution of 20–25 nm, and seemed to be well distinguishable and mostly agglomerate-free. These properties are essential to attain the superparamagnetic property. The morphological changes in both GO nanosheets and Fe_3O_4 NPs during the formation of the rGO/ Fe_3O_4 (5%) nanocomposite were visible in their FE-SEM images, as shown in Fig. 3. The reduction of GO to rGO produced more thin and transparent sheets due to the additional exfoliation of the sheets during the removal of oxygen species.




Figure 3. Field emission-scanning electron microscopy (FE-SEM) images and corresponding EDS spectra of graphene oxide (GO), chitosan (CS), Fe₃O₄, rGO/Fe₃O₄ (5%), and rGO/Fe₃O₄/CS (15%) nanocomposites.




Figure 4. (A–C) High resolution-transmission electron microscopy (HR-TEM) images of rGO/Fe₃O₄/CS (15%) nanocomposites and (D) selected area electron diffraction (SAED) pattern of rGO/Fe₃O₄/CS (15%) nanocomposites.

The Fe₃O₄ NPs with a size distribution of 20–25 nm were encapsulated in the interconnected networks of the rGO sheets. The open edges of the rGO attached to the Fe₃O₄ NPs via functional groups during the formation of rGO/Fe₃O₄ nanocomposite. These interactions tend to strongly prevent the sheets' agglomeration in the matrix and improve the active surface for efficient drug loading and release. The rGO/Fe₃O₄/CS (15%) nanocomposite showed aggregated particles on the surface of GO, increasing the size. This feature is due to the agglomeration of Fe₃O₄ NPs and the changes introduced by CS. After the addition of CS, the particles attached more tightly to the surface of the rGO sheet. Furthermore, the energy-dispersive x-ray spectroscopy (EDX) spectra of all of the samples confirmed the presence of the essential elements in the respective materials, as shown in Fig. 3.

HR-TEM analysis. As shown in Fig. 4A,B, the rGO/Fe₃O₄/CS (15%) nanocomposite was evaluated using the high-resolution transmission electron microscopy (HR-TEM), in which images indicated a homogeneous distribution of Fe₃O₄ and CS with a distorted spherical morphology on the randomly stacked rGO sheet surface. The size distribution of the Fe₃O₄ NPs and CS attached to the rGO sheets was 25–35 nm. The individual Fe₃O₄ and CS particles on the rGO surface were distinguishable, as shown in Fig. 4. The intermediate region of Fe₃O₄, CS, and rGO was uniformly and tightly attached to the rGO sheet's surface, as shown in the HR-TEM images presented in Fig. 4C. The rGO/Fe₃O₄/CS (15%) composites' lattice spacing was measured as 0.25 nm, which corresponds to the (311) plane of the Fe₃O₄ crystal system face-centered cubic system, as shown in the HR-TEM images²⁷. The selected area electron diffraction further investigated the crystalline morphology of Fe₃O₄ NPs incorporated in the nanocomposite (15%). (SAED) (Fig. 4D). The crystalline plane of the Fe₃O₄ system was detected by its diffraction dots and rings represented, which is in agreement with the XRD data.

Chemical state analysis using XPS. The chemical composition, oxidation states of individual elements, and nature of the intermediate bonding between materials in the Fe₃O₄/rGO/CS (15%) nanocomposite were studied using X-ray photoelectron spectroscopy (XPS), and the spectra are shown in Fig. 5A–D. The full-scale survey spectrum indicated the presence of iron, carbon, oxygen, and nitrogen from their characteristic Fe 2p, C 1s, O 1s, and N 1s peaks with binding energy values of 725.3, 284.5, 531.5, and 399.8 eV respectively²⁰ (Fig. 5A). The presence of the Fe 2p peak in the survey spectra was from the Fe₃O₄ NPs, whereas the N 1s peak might have been from the CS group in the composite. The O 1s peak was due to the oxygen species present in all of the three materials. Figure 5D illustrates the high-resolution XPS spectra of Fe 2p. The Fe 2p peak was further deconvoluted into 6 individual peaks, in which the peaks present at 710.8 and 723.9 eV emerged due to the 2p_{3/2} and 2p_{1/2} split orbitals of the Fe²⁺ ions, respectively. The peaks at 712.8 and 725.7 eV were due to the 2p_{3/2} and




Figure 5. X-ray photoelectron spectroscopy (XPS) survey spectra of rGO/Fe₃O₄/CS (15%) nanocomposites (A)—high-resolution spectra of rGO/Fe₃O₄/CS, (B)—C 1s peak, (C)—O 1s peak, and (D)—Fe 2p peak.

2p_{1/2} split orbitals of Fe³⁺ ions. The Fe₃O₄ phase in the prepared nanocomposite was confirmed by the presence of the Fe³⁺ and Fe²⁺ ions.

In the Fe₃O₄ phase, two different Fe sites, which can be represented as [Fe³⁺]A and [Fe³⁺, Fe²⁺]BO₄, were present. The complete tetrahedral A site and partial octahedral B sites were occupied by Fe³⁺ ions, whereas the Fe²⁺ ions occupied only half of the octahedral B. The two small additional peaks present at 719.2 and 731.2 eV represented the satellite peaks of Fe 2p_{3/2} and Fe 2p_{1/2}. Among the four deconvoluted peaks of the C 1s spectra shown in Fig. 5B, the peak at 284.6 eV appeared due to the C–C and C=C species in rGO sheets and cytosine, whereas the peak at 286.1 and 288.4 eV corresponded to the C–NH and C–N bonds present in CS, respectively. A broad peak present at 289.5 eV was a result of the O–C=O bond. The high-resolution O 1s spectra were further deconvoluted to three individual peaks (Fig. 5C). The peak appearing at 529.5 eV was a result of the oxygen atoms bound to Fe in Fe₃O₄. The other two peaks at 531.3 and 532.2 eV represented C–O and C=O, respectively, in rGO and CS.

Magnetic measurements using VSM. Figure 6 illustrates the M–H loop of the rGO/Fe₃O₄/CS (15%) nanocomposite under a maximum induced magnetic field of ±30 kOe at room temperature. The prepared nanocomposite was superparamagnetic with a saturation magnetization (MS) of 5.27 emu/g, attributed to Fe₃O₄ NPs in the composition^{8,20}. However, it should be noted that the obtained MS value was low compared to that of pure Fe₃O₄ NPs according to the previous reports²⁸. This significant decrease in the MS of rGO/Fe₃O₄/CS (15%) nanocomposite may have been due to the existence of a high amount of non-magnetic rGO and CS²⁹. However, the prepared composite showed excellent response in the external magnetic field. The other magnetic parameters, such as remanent magnetization (MR) and coercive field (HC), were 1.23 emu/g and 0.020 kOe. Hence, it can be concluded that the presence of Fe₃O₄ NPs possesses a remarkable effect on the superparamagnetic characteristics of the prepared rGO/Fe₃O₄/CS (15%) nanocomposite.

Pharmacological studies. *In vivo toxicity study of GO, CS, Fe₃O₄, rGO/Fe₃O₄, and rGO/Fe₃O₄/CS nanocomposite in zebrafish embryos.* To assess the biocompatibility and *in vivo* toxicity of the GO, CS, Fe₃O₄, rGO/Fe₃O₄, and rGO/Fe₃O₄/CS nanocomposite, zebrafish *Danio rerio* (*D. rerio*) was chosen as a model animal, due to early embryonic improvement during 120 h, apparent transparency, a similarity with mammals, and easy maintenance^{30,31}. The zebrafish embryos were treated with approximately of 0.1 ng/nL nanomaterials at the 2-cell stage. The embryos were maintained until complete development (72 hpf, hours post fertilization) (Fig. 7).




Figure 6. Vibrating sample magnetometer (VSM) analysis of $rGO/Fe_3O_4/CS$ (15%) nanocomposites.




Figure 7. (A)—Microscopy images taken after microinjection in zebrafish embryos exposed to $30 \mu\text{g/mL}$ of graphene oxide (GO), chitosan (CS), Fe_3O_4 , rGO/Fe_3O_4 (5%), and $rGO/Fe_3O_4/CS$ (15%) for (24, 36, 48 h). (B)—Microscopy images of zebrafish chorions with and without nanoparticles (NPs) treatment (0.1 ng/nL , 72 h).




Figure 8. (A)—Cumulative amount of DOX loading on rGO/Fe₃O₄/CS and rGO/Fe₃O₄/CS/FA nanocomposites, (B)—Linear fitting of the cumulative amount of DOX loading concentration, (C)—Cumulative percentage of pure DOX and rGO/Fe₃O₄/CS/FA/DOX drug releasing at different pH, (D)—Linear fitting of the cumulative percentage of drug release at different pH ($P < 0.05$).

Additionally, the nanocomposite's different material combinations did not impact the survival rate of zebrafish at various developmental stages (from 0 to 72 h), as shown in Fig. 7. This finding was related to the utilization of CS by the embryo as nourishment. Interestingly, our results did not exhibit any abnormalities compared with other materials. Earlier, toxicological studies on mice have presented that graphene strongly improves the dispersity in the physiological medium and enhances biocompatibility^{32,33}. In the present study, rGO/Fe₃O₄/CS exhibited less toxicity and malformations in zebrafish.

In vitro studies on drug loading and pH-regulated release properties of rGO/Fe₃O₄/CS/FA. The loading amount of DOX in the rGO/Fe₃O₄/CS/FA nanocomposite was estimated from its characteristic UV-Vis spectrum at 233 nm by comparing the original DOX concentrations rGO/Fe₃O₄/CS/FA nanocomposite solution to that of the supernatant after loading. Figure 8A shows the images of the rGO/Fe₃O₄/CS/FA nanocomposite loaded with DOX in necessary conditions (pH 7.4). A maximum of 95% of DOX molecules was loaded on the rGO/Fe₃O₄/CS/FA nanocomposite under necessary conditions based on the studies. The saturated loading amount of DOX in the rGO/Fe₃O₄/CS/FA nanocomposite was 0.5 mg/mL⁻¹; therefore, a maximum of 0.448 mg/mL⁻¹ of DOX was loaded³⁴. Sasikala et al.³⁴ claimed the highest loaded amount of drugs on the graphene. However, in this study, the loaded drug amount was higher than that of the reported value. This increased concentration of loaded DOX may be attributed to three significant phenomena: (i) π - π stacking and the H-bonding between GO and DOX (ii) the interaction between the phenolic OH and alkaline amino groups of the DOX molecule with the amino groups and hydroxy on the CS shell of the rGO/Fe₃O₄/CS/FA nanocomposite, which forms intermolecular complexes by hydrogen bonding; (iii) and the mucus nature of the CS shell, which provided physical adsorption, the rGO, which provided high surface volume binding with the OH group, and the superparamagnetic materials, which results in high drug loading efficiency of the synthesized nanocomposite. Although Fe₃O₄ NPs occupied some surface area of GO, a comparable amount of DOX was loaded. This amount of loaded DOX was higher




Figure 9. Relative cell viability of magnetic nano drug carrier (MNDC)/doxorubicin (DOX) and MNDC/DOX/folic acid (FA) loaded magnetic nano drug carrier (MNDC) against (A)—A549 and (B)—MCF-7 cancer cells at different concentrations ($P < 0.05$).

than that found in commonly used nanocarriers, such as polymer micelles, hydrogel microparticles, liposomes, and carbon nanohorns, where the loading amount is reported as below $1 \text{ mg/mg}^{-135-38}$. Additionally, the DOX molecules loaded under necessary conditions were highly efficient and reliable for target delivery because the free carboxylic acid groups can form hydrogen bonds, thus resulting in efficient pH-induced targeted delivery. Additionally, the prepared $\text{rGO/Fe}_3\text{O}_4/\text{CS/FA}$ nanocomposite showed a homogenous dispersion in an aqueous medium due to the carboxylic and hydroxyl groups' existence graphene.

Furthermore, the drug release at 37°C from the composite was studied in simulated body fluid (phosphate-buffered saline; PBS, pH 7.4) and pH 5.5 (PBS). The release profile of DOX from the $\text{rGO/Fe}_3\text{O}_4/\text{CS/DOX/FA}$ nanocomposite into the outer aqueous phase is shown in Fig. 8B. The faster pure DOX release behavior at acidic condition was detected, which was pH-dependent, in which the release value was 25% at pH 7.4 and 81% at pH 5.5. Such a pH-responsive property of MNDC can be practically utilized as a controlled release system, which can gently release doxorubicin in the cancer cell because the pH of intracellular is lower than healthy cells³⁹. Under the two different pH conditions, the cumulative drug release prominently occurred at 10 h, and maximum (96.6% and 10%) drug release was achieved at pH 5.5 and at pH 7.4, respectively. This decrease in drug release at pH 7.4 may be due to DOX's decreased solubility at pH 7.4.

Additionally, the CS polymer was less soluble at pH 7.4, resulting in low permeability. The biodegradable combination of rGO with CS has presented stronger mechanical properties with a large drug delivery capacity, considered a pH-responsive and biodegradable drug delivery system. CS NPs conjugated with drug via pH-cleavable interaction tend to dissociate at the acid condition of endo-lysosomes, and then release the drug into the cytoplasm. The increment in the biodistribution level and drug concentration in the cancer cells is the CS's major anticancer mechanism. CS incorporated with mifepristone controlled the drug release in a constant release behavior and improved the drug's oral bioavailability and anticancer properties via pharmacokinetic study under in vivo analysis⁴⁰. At pH 5.5, the release of DOX was favorable, as the CS polymer was water-soluble, resulting in increased water content and increased permeability of DOX. Because of this pH dependence, DOX can be specifically distributed around tumor tissues rather than non-selective release throughout the body. The pH-dependent release of anticancer drugs was high in acidic conditions. Thus, DOX molecules were protonated and the hydrophobic interactions between DOX molecules and the nanocomposites were decreased in an acidic environment, which accelerated the DOX release. The protonation of DOX molecules and reduced hydrophobic interactions between DOX molecules and the nanocomposites were observed at acidic conditions, which accelerated the DOX release. It demonstrates the potential use of the $\text{rGO/Fe}_3\text{O}_4/\text{CS/DOX/FA}$ nanocomposite in cancer therapy⁴¹.

In vitro cytotoxicity studies of the $\text{rGO/Fe}_3\text{O}_4/\text{CS/DOX/FA}$ nanocomposite. To investigate the cytotoxicity and selective targeting of the $\text{rGO/Fe}_3\text{O}_4/\text{CS/DOX/FA}$ nanocomposite, A549 and MCF7 (cancer) cell lines were incubated FA-free or FA-loaded $\text{rGO/Fe}_3\text{O}_4/\text{CS/DOX/FA}$ nanocomposites in vitro. The cell viability was 20.6% and 8.6% (A549 cells; Fig. 9A), and 18.6% and 7.3% (MCF7 cells; Fig. 9B) for the $\text{rGO/Fe}_3\text{O}_4/\text{CS/DOX/FA}$ and $\text{rGO/Fe}_3\text{O}_4/\text{CS/DOX}$ nanocomposites, respectively, at 1 mg/mL concentration. Besides, cell viability was reduced with the DOX-loaded $\text{rGO/Fe}_3\text{O}_4/\text{CS/FA}$ nanocomposite at a lower 200 mg/mL concentration. Based on these results, the anticancer activity of the released DOX from the nanocomposite was unaffected. Furthermore, A549 cells had lower viability than MCF7 cells after incubation with the vehicles. It shows that the growth inhibition due to $\text{rGO/Fe}_3\text{O}_4/\text{CS/FA}$ was larger in the tumor cells than the normal cells, which can be attributed to the folate receptor-mediated specific endocytosis. As shown in Fig. 9A,B, $\text{rGO/Fe}_3\text{O}_4/\text{CS}$ and $\text{rGO/Fe}_3\text{O}_4/\text{CS/FA}$ nanocomposites showed no obvious cytotoxicity on any material, even after a 48 h incubation, which demonstrated that $\text{rGO/Fe}_3\text{O}_4/\text{CS}$ had excellent cytocompatibility.




Figure 10. Cellular uptake and localization of rGO/Fe₃O₄/CS/DOX (magnetic nano drug carrier (MNDC)/doxorubicin (DOX)) and rGO/Fe₃O₄/CS/DOX/FA (MNDC/DOX/folic acid (FA)) in A549 and MCF-7 cancer cells observed by bright field emission images.

Cancer cells can develop multi-drug resistance (MDR) after treatment with free DOX due to the p-glycoprotein pump's expression in the cell membrane. Due to this expression, the drug molecules can be pumped from the cytosol to the extracellular regions. However, the MDR effect can be avoided when tumor cells uptake polymeric NPs-containing drugs. Even though free DOX is transported into cells by a passive diffusion mechanism, the DOX-loaded rGO/Fe₃O₄/CS/FA nanocomposite is transported by the receptor-mediated endocytosis mechanism. Thus, rGO/Fe₃O₄/CS/DOX/FA is more readily absorbed than free DOX⁴². The inhibition of cancer cell growth is increased synergistically by rGO/Fe₃O₄/CS/DOX/FA. Targeted drug delivery with magnetic nanocarriers facilitates the active transport of drugs into specific regions, resulting in increased drug concentrations at the tumor region compared to routine systemic chemotherapy⁴³.

Cellular uptake, multimodal imaging, and toxicity studies of the rGO/Fe₃O₄/CS/DOX/FA nanocomposite. The DOX release from the nanocomposite and cell nucleus entry is clearly shown in Fig. 10. The bright field emission images of cells incubated with the rGO/Fe₃O₄/CS (magnetic nano-drug carrier (MNDC), rGO/Fe₃O₄/CS/DOX (magnetic nano-drug carrier (MNDC)/DOX) and rGO/Fe₃O₄/CS/DOX/FA (MNDC/DOX/FA) nanocomposites are shown (Fig. 10). DOX is a fluorophore, and its fluorescence emission can evaluate the intracellular activity of rGO/Fe₃O₄/CS, rGO/Fe₃O₄/CS/DOX and DOX-loaded rGO/Fe₃O₄/CS/FA nanocomposite with the A549 and MCF7 cell lines (Fig. 11A,B). The yellow fluorescence from the DOX emissions suggested the significant uptake of rGO/Fe₃O₄/CS/DOX/FA (DOX-loaded folate labeled particles) by the cells. The blue fluorescence, which represents DAPI, clearly indicated that rGO/Fe₃O₄/CS/DOX/FA was primarily localized in the nuclear region. Acridine orange (AO) was utilized to investigate DOX's localization in the perinuclear region and the nucleus. Under blue excitation, the green emission from DOX indicated its binding to the nucleus and cytoplasm⁴⁴.

However, the drug-loaded nanocomposite was primarily internalized in the perinuclear region or in the nucleus, as shown in the image (Fig. 11). The AO fluorescent stain was used to observe the morphological changes in the apoptotic and necrotic cells. The green fluorescence and the yellow emission indicated that the nanocomposites entered into cells with broken membranes, such as apoptotic and dead cells, certain to targeted DNA fragments or apoptotic bodies. Quantitatively, 80% of the cells were apoptotic and necrotic due to the DNA fragment injuries.

Furthermore, to corroborate the folate receptor-mediated drug delivery behavior, we compared the emission of rGO/Fe₃O₄/CS and rGO/Fe₃O₄/CS/DOX (folate unlabeled nanocomposite) to that of rGO/Fe₃O₄/CS/DOX/FA. The loading efficiency for the rGO/Fe₃O₄/CS/DOX/FA nanocomposite was 98%. The rGO/Fe₃O₄/CS/DOX/FA nanocomposite had higher uptake into the cancer cells, as these particles were conjugated with folic acid and cancer cells over-express folate receptors. Thus, the application of folic acid-conjugated Fe₃O₄ NPs for drug carriers could remarkably improve the uptake of DOX in cancer cells that over-express folate receptors. Based on these results, rGO/Fe₃O₄/CS/DOX/FA improved therapeutic efficacy by the synergistic effect of specific targeting, effective drug delivery, and improved anticancer activity of DOX. This mechanism is based on classical chemotherapy and the modern nanotechnology with rGO/Fe₃O₄/CS superparamagnetic NPs. Additionally, these nanocomposites can also treat the cancer cells by hyperthermia and photodynamic therapy and facilitate tumor imaging via their fluorescence property.

Antibiofilm activity. The binding structure of AO to adherent cells caused by the in vitro biofilm formation of GO, CS, Fe₃O₄ NPs, rGO/Fe₃O₄, and rGO/Fe₃O₄/CS nanocomposites was observed using confocal laser scanning microscopy (CLSM). The bacteria *Streptococcus pneumoniae* (*S. pneumoniae*), *Pseudomonas aeruginosa* (*P.*




Figure 11. Cellular uptake and localization of rGO/Fe₃O₄/CS/DOX (magnetic nano drug carrier (MNDC)/doxorubicin (DOX)) and rGO/Fe₃O₄/CS/DOX/FA (MNDC/DOX/FA) in (A)—A549 and (B)—MCF-7 cancer cells observed by fluorescence microscopy images.

aeruginosa), and fungus *Candida albicans* (*C. albicans*), have been studied in detail concerning their ability to form biofilms⁸. The Fe₃O₄ NPs with a minimum inhibitory concentration (MIC) of 50 μg had a minimal effect compared to the control on the biofilm structure and the proportion of the live bacteria in the biofilm after a 12 h incubation. After a 24 h incubation period with Fe₃O₄ NPs, a decrease in biofilm formation was observed to increase NPs concentration (Fig. 12; 74% inhibition of biofilm was observed for the rGO/Fe₃O₄/CS nanocomposite, while 63% inhibition of biofilm was observed for the rGO/Fe₃O₄ nanocomposite).

However, there were still quite a lot of biofilm structures remaining and the number of dead microbes significantly increased, indicating the biofilm ability of NPs. Results show that NPs induce the biofilm formation by *P. aeruginosa*, *S. aureus*, and *C. albicans*; however, the concentration of the NPs should be continuously increased for the biofilm to be destroyed. Therefore, the rGO/Fe₃O₄/CS nanocomposite destroyed a maturely formed biofilm structure and controlled the thickness by breaking the exopolysaccharides.

Antioxidant activity. The 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay was utilized to investigate the nanomaterials' antioxidant activity in which ascorbic acid was considered positive control. DPPH is a stable compound that accepts hydrogens or electrons, and the reduction of DPPH is directly proportional to the samples' antioxidant nature. The free-radical scavenging ability of GO, CS, Fe₃O₄ NPs, rGO/Fe₃O₄ nanocomposite, and rGO/Fe₃O₄/CS nanocomposite as compared to the material combination as shown in (Fig. 13A,B). It reveals that both materials show free radical scavenging ability dependent on their materials. The free radical % scavenging potential of control, GO, CS, Fe₃O₄ NPs, rGO/Fe₃O₄ nanocomposite, and rGO/Fe₃O₄/CS nanocomposite were 0%, 48%, 58.6%, 66%, 76.6%, and 87.6%, respectively, based on the DPPH activity (Fig. 13A,B). The nanomaterials showed enhanced scavenging activity, increasing DPPH scavenging potential for CS, Fe₃O₄ NPs, and rGO. Lower concentrations of the polymer-coated nanocomposite reflected its higher potency for free radical scavenging and total antioxidant capacity. Similar trends in the improvement of DPPH scavenging behavior by GO, Fe₃O₄ NPs, and CS NPs have been previously reported^{45–48}.




Figure 12. (A)—Light microscopy images of biofilms with crystal violet stain, (B) confocal laser scanning microscopy (CLSM) images of maturely formed microbial biofilms exposed to graphene oxide (GO), chitosan (CS), Fe₃O₄, rGO/Fe₃O₄ (5%), and rGO/Fe₃O₄/CS (15%) at 37 °C for 24 h. In the CLSM images, live microbes emit green light, while the dead cells were not colored.

Conclusions

We have developed a hybrid system by the solvothermal method that was highly biocompatible, water dispersible, fluorescent, superparamagnetic, and multifunctional. This hybrid possesses a large loading capacity of approximately 0.448 mg/mL⁻¹ with the DOX anticancer drug. The release of DOX can be pH-triggered and controlled magnetically. Specifically, the surface modification of Fe₃O₄ NPs with folic acid improved its uptake by cancer cells. The toxicological study revealed the cytocompatible nature of rGO/Fe₃O₄/CS nanocomposite in A549 and MCF7 cells. In vitro cellular imaging of rGO/Fe₃O₄/CS/DOX/FA in A549 and MCF7 cells showed significant co-localization to the cytoplasmic region. The toxicity studies showed high biocompatibility of the rGO/Fe₃O₄/CS to zebrafish without inducing significant abnormalities.

Additionally, the zebrafish survival rate was not affected. Uniform distribution over the entire body was observed zebrafish using In vivo whole-animal imaging of rGO/Fe₃O₄/CS. Besides, rGO/Fe₃O₄/CS nanocomposite highly efficient in disrupting the biofilm formed by *S. aureus*, *P. aeruginosa* and *C. albicans* and also exert productive antioxidant potential. Hence, rGO/Fe₃O₄/CS may serve as a biologically potent multipurpose material for future biomedical investigations and could be applied as a nano-deliver agent (nanocarrier) to the combination of photodynamic therapy with gene delivery or magnetically-guided drug.

Materials and methods

Chemicals and reagents. Graphite powder, ferric chloride (FeCl₃·6H₂O) (99%), ferrous sulfate (FeSO₄·7H₂O) (99.5%), sodium nitrate (NaNO₃) (99%), sodium hydroxide (NaOH) (97%), potassium permanganate (KMnO₄) (99%), sulfuric acid (H₂SO₄) (95–97%), folic acid (FA) (97%), glutaraldehyde (98%), sucrose (99%), and ethylene glycol (EG) (99%) were purchased from Merck (India). Chitosan (CS) powder (medium molecular weight- 190,000 to 310,000 Da) with a deacetylation degree of 85%, and doxorubicin hydrochloride (98% with 2 years of validation days) were purchased from Sigma-Aldrich (India). Microbial cultures (*Strepto-*




Figure 13. (A)—Total antioxidant capacity ($\mu\text{g}/\text{mg}$) and (B)—% radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging activity of graphene oxide (GO), chitosan (CS), Fe_3O_4 , rGO/ Fe_3O_4 (5%), and rGO/ Fe_3O_4 /CS (15%) ($P < 0.05$).

coccus pneumoniae (MTCC 1936), *Pseudomonas aeruginosa* (MTCC 2642) and *Candida albicans* (MTCC 3959) were received from Microbial Type Culture Collection and Gene Bank (MTCC), Chandigarh, India and all media were supplied by Himedia (India). The analytical grade of chemical was used. The entire work was carried out using Milli-Q water.

Material synthesis. *Preparation of graphene oxide.* Modified Hummer's method was used to prepare to GO. The graphene oxide was prepared based on the Hummer's method with some modification. Briefly, graphite powder (2 g) and NaNO_3 (2 g) were mixed to 100 mL of concentrated sulfuric acid. After stirring the mixture in an ice bath for half an hour, 7 g of KMnO_4 was added to the solution. Afterward, the solution was further stirred for 1 h at ambient condition. Next, the solution was stirred overnight in order to oxidize the graphite. One hundred milliliters of Milli-Q water was poured into the mixture to neutralize. An additional 400 mL of Milli-Q water was added, and the mixture was stirred for 30 min. Next, 10 mL of 30% hydrogen peroxide was added to terminate the reaction. Finally, the solution was subjected to stirring, centrifugation, and then washing (with 5% HCl) until the pH became close to 7. The resultant was separated by filtration and extensively washed with H_2O ; the obtained GO was then freeze-dried.

Synthesis of Fe_3O_4 NPs. The solvothermal method was utilized to prepare Fe_3O_4 NPs. $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ (2 mM), $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ (1 mM), and sucrose (0.1 mM) were added to 50 mL of ethylene glycol and dissolved by stirring vigorously. Subsequently, pH was adjusted by adding NaOH dropwise into the solution and further stirred for 30 min. As soon as the color changed from orange to black, a black precipitate was noticed. The resulting solution was immediately transferred to a Teflon-lined stainless autoclave at 150 °C for 24 h. The mixture was allowed to reach room temperature by slow cooling. The resulting precipitate containing the Fe_3O_4 NPs was harvested using a permanent magnet discarding the supernatant. The precipitate was washed thrice with Milli-Q water and acetone. Finally, the precipitate was freeze-dried.

Synthesis of the rGO/Fe₃O₄ nanocomposite. A dispersion of GO (10 mg) in Milli-Q water (10 mL) and ethylene glycol (10 mL) was prepared by ultrasonication for 3 h. Then, 0.1 M ferric chloride, 0.05 M ferrous sulfate and sucrose were added to the dispersion while stirring the dispersion vigorously. Then, the pH of the mixture (12) was adjusted by the drop addition of NaOH. Following this, ascorbic acid (10 mg) was added as a reducing agent under continuous stirring for 1 h. The mixture was transferred into a stainless steel autoclave at 150 °C for 24 h. The solution was centrifuged to separate and wash the resulting nanocomposite (thrice) with water/acetone and freeze-dried.

Preparation of amphiphilic polymer rGO/Fe₃O₄/CS nanocomposite. The biocompatible rGO/Fe₃O₄ nanocomposite was fabricated by grafting the chitosan's functional groups on the NP surface. Under vigorous stirring, the CS powder was dissolved in 2% acetic acid at 25 ± 2 °C for about 2 days, and the solution was neutralized. To introduce CS functionalization, 10 mL of rGO/Fe₃O₄ nanocomposite (0.3 mg/mL) was mixed with 5 mL of CS (40 mg/mL with different concentrations 5, 10, and 15%) and sonicated for 30 min. To this mixture, 3 mL of 1% glutaraldehyde was added and stirred at 1000 rpm for 24 h. Hydrophilic and biocompatible rGO/Fe₃O₄/CS nanocomposite was obtained from the solution, washed with Milli-Q water.

Material characterization techniques. The infrared spectral studies were carried out using a Perkin-Elmer FT-IR spectrophotometer using KBr pellet. The crystalline structural analysis was performed using a PW3040/60 Xpert PRO X-ray diffractometer with Cu K α radiation and a wavelength of 1.54060 Å. Microstructures of the pure and nanocomposite were examined by FE-SEM (Model: Hitachi S-4500). The chemical compositional analysis was studied using the EDX. HR-TEM (Tecnai) was used to study the particle size and nature. The chemical state analysis was performed with XPS (Carl Zeiss) using Al K α excitation at 250 W. The room temperature magnetization was measured by a vibrating sample magnetometer (VSM, Lake Shore, Model-7410, USA). The samples were also analyzed by UV-Vis spectroscopy (Shimadzu UV/Vis 1800 spectrophotometer), and the absorbance was measured at 620 nm using a Thermo Multiskan ELISA multiwell plate reader (EX, USA). The morphology of the A549 and MCF7 cells was studied using Nikon (Japan) bright-field inverted light microscopy at 40X magnification and fluorescence microscope (Nikon Eclipse, Inc, Japan) at 400X magnification with an excitation filter at 480 nm. Biofilm inhibition was inspected by light microscopy (Olympus cx21i) CLSM (NIKON ECLIPSETS 100) at a magnification of 20X.

Pharmacological Study. *Microinjection of GO, CS, Fe₃O₄ NPs, rGO/Fe₃O₄ (5%), and rGO/Fe₃O₄/CS (15%) into zebrafish embryos and microscopic measurements.* Wild-type AB strains of *Danio rerio* (*D. rerio*-zebrafish) embryos were supplied from the zebrafish core facility center, National Tsing Hua University. The MNDC samples were ultrasonicated for 30 min in Milli-Q water and then microinjected (10 nL) in the fresh embryos placed on the microinjection embryo tray. The dark incubated (28 °C) control embryos (without MNDC) and MNDC-loaded embryos were periodically observed using microscopic images^{49,50}. The abnormality of infant fish was detected using a MicroFire camera (Olympus CX-21i Trinocular Microscope, LED illumination) mounted onto a Leica MZ16 stereomicroscope (Meyer Instruments, Houston, TX, USA).

Targeted drug delivery. *Preparation of folate conjugated rGO/Fe₃O₄/CS (15%) nanocomposite.* For the sufficient attachment of folic acid to the rGO/Fe₃O₄/CS (15%) nanocomposite, we adapted a method reported by Guo et al. in which 20 mg of the rGO/Fe₃O₄/CS (15%) nanocomposite was washed and resuspended with dimethyl sulfoxide (DMSO). About 0.1 mg of FA and 0.05 μ L of (3-aminopropyl) triethoxysilane (APTS) were dissolved in 1 mL of DMSO in a flask. Then, 0.03 mg of N-hydroxysuccinimide and 0.05 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride were added to the flask and stirred for 2 h. In another flask, 4 mL of toluene was taken. The nanocomposite DMSO suspension and the folate-APTS solution were added to toluene. The solution was stirred for 20 h at ambient conditions. The folate conjugated nanocomposite was thoroughly centrifuged and rinsed with toluene, and vacuum-dried.

Preparation of drug encapsulated nanocomposite (rGO/Fe₃O₄/CS/FA/DOX). The anticancer drug DOX was encapsulated in rGO/Fe₃O₄/CS and rGO/Fe₃O₄/CS/FA in various concentrations by a simple mixing technique to initiate physisorption⁵¹. Initially, 10 mg of DOX were mixed in 5 mL of PBS buffer with pH 7.4 and then dispersed by ultrasonication for 10 min. Various concentrations of DOX (0.05, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5 and 5% mg/mL) were prepared from the stock (10 mg in 5 mL) solution by serial dilutions (in triplicate), and were subjected to 2 min of sonication. To each of the drug suspensions, a known and fixed amount of rGO/Fe₃O₄/CS/FA (100 μ g/mL) was added and incubated for 24 h. The drug-loaded nanocomposite was centrifuged to separate the free drug molecules at 12,000 rpm for 10 min and maintained at 4 °C before further analysis. The drug concentration was measured using UV-Vis spectra of the supernatant and comparison with a calibration curve. The amount of drug-loaded in the rGO/Fe₃O₄/CS/DOX/FA was determined by comparing the supernatant's concentration to that of the free drug molecules taken initially.

Kinetics of pH-dependent drug release. The pH-dependent DOX release from the rGO/Fe₃O₄/CS/FA/DOX was analyzed by making a suspension of rGO/Fe₃O₄/CS/FA/DOX with a constant content of DOX dissolved in PBS buffer at physiological (pH 7.4) and acidic (pH 5.5) pH levels. The quantity of drug released from the nanocomposite was estimated from the UV-vis absorption spectra of 1 mL of released PBS taken from both samples at regular time intervals. The samples were simultaneously maintained under an exact temperature of 37 °C in a shaking incubator. The volume of PBS withdrawn for analysis was replaced with the same volume of fresh PBS.

All of the measurements were done in triplicates. The control graph measured the actual releasing rate at various pHs, and the drug content loaded into the rGO/Fe₃O₄/CS/FA/DOX was calculated by equation.

Maintenance of cell lines. Experimental cell lines include A549 and MCF7 were supplied from the National Centre for Cell Sciences (NCCS), Pune, India. The cell lines were sustained in Dulbecco's modified eagles medium (DMEM), holding 10% Fetal bovine serum (FBS). The cells were sustained in a humidified CO₂ incubator according to procedure⁴².

Cytotoxic analysis. The toxic activity of MNDC, MNDC/DOX and MNDC/DOX/FA against cancer cell lines were studied using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] test⁴⁹. Certain cancer cell lines (1 × 10⁴ cells/well) were introduced into the well of 96-well plate at their IC₅₀ values. The medium was introduced with serially diluted MNDC, MNDC/DOX and MNDC/DOX/FA, and allowed to incubate for 48 h. After incubation, the medium was substituted with 100 μL of the MTT solution and incubated at 37 °C for 4 h. The plate was read at 620 nm in an ELISA multi-well plate reader (ThermoMultiskan EX, USA). The cell viability was calculated using the below formula, Cell viability (%) = Absorbance value of treated sample/ Absorbance value of control × 100.

Morphological analysis. Change in the morphology of the A549 and MCF-7 cancer cell lines (1 × 10⁵ cells/cover slip) concerning the release of drugs, which was probed using MNDC, MNDC/DOX and MNDC/DOX/FA. The coverslips presented on the clean glass slides were detected using a Nikon (Japan) bright-field inverted light microscopy at 40X magnification.

Apoptotic analysis. The cell suspension (1 × 10⁵ cells/mL) was stained using ethidium bromide (EthBr) (100 mg/mL) and AO and mildly spread on the slide to investigate apoptosis. The cancer cell lines were gently flooded with Na₂HPO₄-KH₂PO₄ buffer solution (pH 7.2) before AO/EtBr staining. Afterward, the cells were rinsed with PBS twice and evaluate under a fluorescence microscope at 40X magnification with an excitation filter at 480 nm. The (4',6-diamidino-2-phenylindole) DAPI analysis was conducted based on the same protocol⁵².

Antibiofilm assessment. The samples' potential antibiofilm ability was investigated using *S. pneumonia*, *P. aeruginosa*, and *C. albicans* as Gram-positive, Gram-negative, and fungus, respectively. Briefly, The fungal and bacterial biofilm was grown on the sterile glass submerged potato dextrose broth and nutrient broth, respectively. Afterward, the nanomaterials were individually added to each well and incubated at 37 °C for 24 h. Consequently, the loosely attached cells on the glass were thoroughly removed using PBS, and the glass was stained nucleic acid fluorescent dye AO (0.4%). Finally, samples were evaluated using under CLSM (Carl Zeiss LSM 710) with a 488 nm argon laser using a BP 500–640 bandpass emission filter Zen 2009 software (Carl Zeiss, Germany)⁵³.

Antioxidant assay. Free radicals quenching property of GO, CS, Fe₃O₄ NPs, rGO/Fe₃O₄ (5%), and rGO/Fe₃O₄/CS (15%) were assessed using DPPH and reducing power method, as described below.

DPPH radical scavenging analysis. DPPH was used to measure the antioxidant activity of GO, CS, Fe₃O₄ NPs, rGO/Fe₃O₄ (5%), and rGO/Fe₃O₄/CS (15%) based on a previously reported method⁴². DPPH stock was prepared in 40 mL of acetate buffer (0.1 M, pH 5.5) with methanol(40 mL: 60 mL) and maintained for 30 min at 30 °C in dark conditions and detected at 520 nm. Ascorbic acid was considered as a positive control⁵³.

Reducing power analysis. The total reducing power of GO, CS, Fe₃O₄ NPs, rGO/Fe₃O₄ (5%), and rGO/Fe₃O₄/CS (15%) was assessed by the following method. Briefly, 0.1 mg/mL in 500 μL of d.H₂O was mixed in 2.5 mL of phosphate buffer (0.2 mL, pH 6.6). To this solution, 2.5 mL of potassium ferricyanide (1%) was introduced and incubated for 20 min at 50 °C. Subsequently, 2.5 mL of 10% trichloroacetic acid (TCA) was mixed and incubated for 10 min. Afterward, 2.5 mL of d.H₂O and 0.5 mL of ferric chloride (0.01%) were added with the supernatant and was detected at 700 nm in the UV-vis spectrometer against phosphate buffer as a blank⁵³.

Statistical assessment. The analysis was made with a one-way analysis of variance (ANOVA) with significance levels at p < 0.05. All data were shown as mean ± standard deviation values.

Received: 31 August 2019; Accepted: 22 October 2020

Published online: 03 November 2020

References

- Arias, J. L., Reddy, L. H. & Couvreur, P. Fe₃O₄/chitosan nanocomposite for magnetic drug targeting to cancer. *J. Mater. Chem.* **22**, 7622–7632 (2012).
- Arias, J. L., Linares-Molinero, F., Gallardo, V. & Delgado, Á. V. Study of carbonyl iron/poly (butylcyanoacrylate)(core/shell) particles as anticancer drug delivery systems: Loading and release properties. *Eur. J. Pharm. Sci.* **33**, 252–261 (2008).
- Gazeau, F., Levy, M. & Wilhelm, C. Optimizing magnetic nanoparticle design for nanothermotherapy. *Nanomedicine* **3**, 831–844 (2008).
- Chandra, S., Dietrich, S., Lang, H. & Bahadur, D. Dendrimer-doxorubicin conjugate for enhanced therapeutic effects for cancer. *J. Mater. Chem.* **21**, 5729–5737 (2011).

5. Barick, K. C. *et al.* pH-responsive peptide mimic shell cross-linked magnetic nanocarriers for combination therapy. *Adv. Funct. Mater.* **22**, 4975–4984 (2012).
6. Sahoo, B. *et al.* Thermal and pH responsive polymer-tethered multifunctional magnetic nanoparticles for targeted delivery of anticancer drug. *ACS Appl. Mater. Interfaces*. **5**, 3884–3893 (2013).
7. Spinato, C., MénardMoyon, C. & Bianco, A. Chemical functionalization of graphene for biomedical applications. *Funct. Graph.* <https://doi.org/10.1002/9783527672790.ch4> (2014).
8. Basith, N. M. *et al.* *J. Supercond. Nov. Magn.* **29**, 2053–2058 (2016).
9. Goenka, S., Sant, V. & Sant, S. Graphene-based nanomaterials for drug delivery and tissue engineering. *J. Control Release* **173**, 75–88 (2014).
10. Park, S. *et al.* Colloidal suspensions of highly reduced graphene oxide in a wide variety of organic solvents. *Nano Lett.* **9**, 1593–1597 (2009).
11. Kim, J. *et al.* Graphene oxide sheets at interfaces. *J. Am. Chem. Soc.* **132**, 8180–8186 (2010).
12. Guo, F. *et al.* Hydration-responsive folding and unfolding in graphene oxide liquid crystal phases. *ACS Nano* **5**, 8019–8025 (2011).
13. Kim, F., Cote, L. J. & Huang, J. Graphene oxide: Surface activity and two-dimensional assembly. *Adv. Mater.* **22**, 1954–1958 (2010).
14. Wang, K. *et al.* Biocompatibility of graphene oxide. *Nanoscale. Res. Lett.* **6**, 8 (2011).
15. Wang, C. *et al.* Multifunctional chitosan magnetic-graphene (CMG) NPs: A theragnostic platform for tumor-targeted co-delivery of drugs, genes and MRI contrast agents. *J. Mater. Chem B* **1**, 4396–4405 (2013).
16. Rinaudo, M. Chitin and chitosan: Properties and applications. *Prog. Polym. Sci.* **31**, 603–632 (2006).
17. Haggerty, T. J. *et al.* Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells. *Cancer. Immunol. Immunother.* **60**, 133–144 (2011).
18. McCarthy, J. R., Bhaumik, J., Karver, M. R., Erdem, S. S. & Weissleder, R. Targeted nanoagents for the detection of cancers. *Mol. Oncol.* **4**, 511–528 (2010).
19. Mei, L. *et al.* Pharmaceutical nanotechnology for oral delivery of anticancer drugs. *Adv. Drug. Deliver. Rev.* **65**, 880–890 (2013).
20. Sahoo, B. *et al.* Thermal and pH responsive polymer-tethered multifunctional magnetic nanoparticles for targeted delivery of anticancer drug. *ACS Appl. Mater. Interfaces* **5**, 3884–3893 (2013).
21. Kuchlyan, J., Kundu, N., Banik, D., Roy, A. & Sarkar, N. Spectroscopy and fluorescence lifetime imaging microscopy to probe the interaction of bovine serum albumin with graphene oxide. *Langmuir* **31**, 13793–13801 (2015).
22. Van Hoa, N., TrungKhong, T., Hoang Quyen, T. T. & Si Trung, T. One-step facile synthesis of mesoporous graphene/Fe₃O₄/chitosan nanocomposite and its adsorption capacity for a textile dye. *J. Water Process Eng.* **9**, 170–178 (2016).
23. Yang, X. *et al.* Superparamagnetic graphene oxide Fe₃O₄NPs hybrid for controlled targeted drug carriers. *J. Mater. Chem.* **19**, 2710–2714 (2009).
24. Yadav, M., Rhee, K. Y., Park, S. J. & Hui, D. Mechanical properties of Fe₃O₄/GO/CS composites. *Compos. Part B -Eng.* **66**, 89–96 (2014).
25. Zheng, B. *et al.* Green preparation of reduced graphene oxide for sensing and energy storage applications. *Sci. Reports.* **4**, 1–8 (2014).
26. Holger, B. *et al.* Determination of nano crystal sizes: A comparison of TEM, SAXS, and XRD studies of highly monodisperse-CoPt₃ particles. *Langmuir* **21**, 1931–1936 (2005).
27. Yang, Z. *et al.* Encapsulation of Fe₃O₄ nanoparticles into N, S co-doped graphene sheets with greatly enhanced electrochemical performance. *Sci. Rep.* **6**, 27957 (2016).
28. Vitalii, P. *et al.* Superparamagnetic Fe₃O₄ nanoparticles: synthesis by thermal decomposition of iron(III) glucuronate and application in magnetic resonance imaging. *ACS Appl. Mater. Interfaces* **8**, 7238–7247 (2016).
29. Liu, Y. W. *et al.* Facile and straightforward synthesis of superparamagnetic reduced graphene oxide–Fe₃O₄ hybrid composite by a solvothermal reaction. *Nanotechnology* **24**, 025604 (2012).
30. Giacomotto, J. & Ségalat, L. High-throughput screening and small animal models, where are we?. *Br. J. Pharmacol.* **160**, 204–216 (2010).
31. Lee, K. Y. *et al.* Zebrafish models for functional and toxicological screening of nano scale drug delivery systems: Promoting pre-clinical applications. *Biosci. Rep.* **37**, 1–13 (2017).
32. Yang, K. *et al.* In vivo pharmacokinetics, long-term biodistribution, and toxicology of PEGylated graphene in mice. *ACS Nano* **5**, 516–522 (2010).
33. Liu, C. W. *et al.* Graphene-based anticancer nanosystem and its bio safety evaluation using a zebrafish model. *Biomacromol* **14**, 358–366 (2013).
34. Sasikala, A. R. *et al.* Multifunctional nano carpets for cancer theranostics: Remotely controlled graphene nano heaters for thermo-chemo sensitisation and magnetic resonance imaging. *Sci. Rep.* **6**, 20543 (2016).
35. Jhaveri, A. M. & Torchilin, V. P. Multifunctional polymeric micelles for delivery of drugs and siRNA. *Front. Pharmacol.* **5**, 77 (2014).
36. Cavalieri, F. *et al.* Novel PVA-based hydrogel microparticles for doxorubicin delivery. *Biomacromol* **9**, 1967–1973 (2008).
37. Chi, Y. *et al.* Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models. *J. Control Release* **261**, 113–125 (2017).
38. Karousis, N., Suarez-Martinez, I., Ewels, C. P. & Tagmatarchis, N. Structure, properties, functionalization, and applications of carbon nanohorns. *Chem. Rev.* **116**, 4850–4883 (2016).
39. Nogueira, J. *et al.* Magnetic driven nanocarriers for pH-responsive doxorubicin release in cancer therapy. *Molecules* **25**, 333 (2020).
40. Adhikari, H. S. & Yadav, P. N. Anticancer activity of chitosan, chitosan derivatives, and their mechanism of action. *Int. J. Biomater.* **2018**, 2952085 (2018).
41. Lai, H., Lu, M., Lu, H., Stenzel, M. H. & Xiao, P. pH-Triggered release of gemcitabine from polymer coated nano diamonds fabricated by RAFT polymerization and copper free click chemistry. *Polym. Chem.* **7**, 6220–6230 (2016).
42. Chen, M. L., He, Y. J., Chen, X. W. & Wang, J. H. Quantum dots conjugated with Fe₃O₄-filled carbon nanotubes for cancer-targeted imaging and magnetically guided drug delivery. *Langmuir* **28**, 16469–16476 (2012).
43. Kim, J. *et al.* Designed fabrication of a multifunctional polymer nano medical platform for simultaneous cancer-targeted imaging and magnetically guided drug delivery. *Adv. Mater.* **20**, 478–483 (2008).
44. Karthika, V. *et al.* Biocompatible properties of nano-drug carriers using TiO₂-Au embedded on multiwall carbon nanotubes for targeted drug delivery. *Mater. Sci. Eng. C* **90**, 589–601 (2018).
45. Qiu, Y. *et al.* Antioxidant chemistry of graphene-based materials and its role in oxidation protection technology. *Nanoscale.* **6**, 11744–11755 (2014).
46. Nazarzadeh Zare, E., Lakouraj, M. M. & Baghayeri, M. Electro-magnetic polyfuran/Fe₃O₄ nanocomposite: Synthesis, characterization, antioxidant activity, and its application as a biosensor. *Int. J. Polym.* **64**, 175–183 (2015).
47. Paul, S. S., Saikia, J. P., Samdarshi, S. K. & Konwar, B. K. Investigation of antioxidant property of iron oxide particles by 1'-1' diphenylpicryl-hydrazyle (DPPH) method. *J. Magn. Magn. Mater.* **321**, 3621–3623 (2009).
48. Rahaiee, S., Hashemi, M., Shojaosadati, S. A., Moini, S. & Razavi, S. H. Nanoparticles based on crocin loaded chitosan-alginate biopolymers: Antioxidant activities, bioavailability and anticancer properties. *Int. J. Biol. Macromol.* **99**, 401–408 (2017).
49. Wang, C.-H. *et al.* Zebrafish Thsd7a is a neural protein required for angiogenic patterning during development. *Dev. Dyn.* **240**, 1412–1421 (2011).
50. Gollavelli, G. & Ling, Y. C. Multi-functional graphene as an in-vitro and in-vivo imaging probe. *Biomaterials* **33**, 2532–2545 (2012).

51. Rao, W. *et al.* Chitosan-decorated doxorubicin-encapsulated nanoparticle targets and eliminates tumor reinitiating cancer stem-like cells. *ACS Nano* **9**, 5725–5740 (2015).
52. Limsuwan, S. & Voravuthikunchai, S. P. *Boesenbergia pandurata* (Roxb) Schltr, *Eleutherine americana* Merr and *Rhodomyrtus tomentosa* (Aiton) Hassk as antibiofilm producing and antiquorum sensing in *Streptococcus pyogenes*. *Immunol. Med. Microbiol.* **53**, 429–436 (2008).
53. Brand, W., Cuvelier, M. E. & Berset, C. Use of a free radical method to evaluate antioxidant activity. *Lebenson Wiss Technol.* **28**, 25–30 (1995).

Acknowledgements

The authors acknowledge the Deanship of Scientific Research, King Saud University for funding through Vice Deanship of Scientific Research Chairs. The authors express deep gratitude to the Deanship of Scientific Research, RSSU at King Saud University for their technical support.

Author contributions

V.K., K.G., A.A. and M.G. conceived of the idea, developed the theory, and performed the experiments. M.G., M.S.A. and S.D. reviewed and verified the data and manuscript. M.S.A. and S.D. contributed to characterize, analyze, and performed the experiments and write the manuscript. V.K., K.G., A.A. and M.G. were involved in experiments, results, and discussions. All authors have discussed the results and the final version of the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to M.S.A.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020